<DOC>
	<DOCNO>NCT00869908</DOCNO>
	<brief_summary>This study conduct Africa , Asia , South America Europe . The aim observational study document experience study insulin use routine clinical practice . After physician 's decision start insulin treatment use NovoMix® 30 , Levemir® NovoRapid® ( alone combine ) , type 2 diabetic eligible include study physician 's discretion</brief_summary>
	<brief_title>Observational Study Effect NovoMix® 30 , Levemir® NovoRapid® ( Alone Combined ) Type 2 Diabetics Previously Treated With Anti-diabetic Medication</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>After physician take decision use NovoMix®30 , Levemir® NovoRapid® ( alone combine ) , subject type 2 diabetes treat insulin start insulin within last 4 week inclusion study eligible study . The selection subject discretion individual physician . Subjects treat NovoMix® 30 , Levemir® NovoRapid® ( alone combination ) 4 week inclusion study . Subjects previously enrol study . Subjects hypersensitivity NovoMix® 30 , Levemir® NovoRapid® excipients . Women pregnant , breast feeding intention become pregnant within next 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>